Patents Assigned to Institute Pasteur
  • GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI
    Publication number: 20140161793
    Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
    Type: Application
    Filed: December 14, 2011
    Publication date: June 12, 2014
    Applicants: INSERM, INSTITUT PASTEUR, Centre National De La Recherche Scientifique
    Inventors: Armelle PHALIPON, Farida NATO, Laurence MULARD, Philippe SANSONETTI, Francoise BALEUX, Frederic BELOT, Cyrille GRANDJEAN
  • Identification of virulence associated regions RD1 and RD5 leading to improve vaccine of BCG and
    Patent number: 8747866
    Abstract: The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli, especially the ESAT-6 and CFP-10 genes. These strains will be referred as the M. bovis BCG::RD1 or M. microti::RD1 strains and are useful as a new improved vaccine for preventing tuberculosis and as a therapeutical product enhancing the stimulation of the immune system for the treatment of bladder cancer.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: June 10, 2014
    Assignee: Institut Pasteur
    Inventors: Stewart Cole, Alexander S. Pym, Roland Brosch, Priscille Brodin, Laleh Majlessi, Caroline Demangel, Claude LeClerc
  • ATTENUATED PLASMODIUM WITH DEACTIVATED HMGB2 GENE, AS VACCINE
    Publication number: 20140154289
    Abstract: The present invention relates to novel compositions and methods for immunizing a host against malaria using a Plasmodium parasite genetically attenuated via the inactivation of the function of the hmgb2 gene.
    Type: Application
    Filed: July 19, 2012
    Publication date: June 5, 2014
    Applicants: INSTITUT PASTEUR, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)
    Inventors: Catherine Vaquero, Sylvie Briquet, Nadou Essenia Lawson-Hogban, Salaheddine Mecheri, Robert Menard
  • Anti-Inflammation Compounds
    Publication number: 20140155387
    Abstract: The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR4, C?O, C?S, OP(O)(O), P?O, CH2, or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C?O, O, S, CH2, or NR5; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis.
    Type: Application
    Filed: April 20, 2012
    Publication date: June 5, 2014
    Applicants: QURIENT, CO. LTD., INSTITUT PASTEUR KOREA
    Inventors: Zaesung No, Jaeseung Kim, Sung-Jun Han, Jung Hwan Kim, Young Sam Park, Sangchul Lee, Kiyean Nam, Jeongjun Kim, Jinhwa Lee, Sunhee Kang, Min Jung Seo, Saeyeon Lee, Gahee Choi
  • HCV-derived polypeptides and uses thereof
    Patent number: 8735346
    Abstract: The present invention relates to Hepatitis C virus (HCV)-derived polypeptides and nucleic acid molecules encoding same which advantageously comprises a cd81-binding region. In this connection, the present invention specifically relates to the use of the polypeptides or nucleic acid molecules in compositions and methods for the prevention, the treatment and the diagnosis of HCV infections.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: May 27, 2014
    Assignee: Institut Pasteur
    Inventors: Thomas Krey, Felix A. Rey, Carlos Massayuki Kikuti, Laurence Damier-Piolle
  • Rapid detection of the “high-virulent” ST-17 clone of group B
    Patent number: 8735565
    Abstract: The present invention relates to polynucleotides enabling the rapid, simple and specific detection of Group B Streptococcus highly-virulent ST-17 clones. The present invention also relates to the polypeptides encoded by the polynucleotides, as well as to antibodies directed or raised against the polypeptides. The present invention also relates to kits and methods for the specific detection of Group B Streptococcus highly-virulent ST-17 clones, using the polynucleotides, the polypeptides or the antibodies according to the invention.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: May 27, 2014
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique, Universite Paris Descartes, Assistance Publique-Hospitaux de Paris
    Inventors: Claire Poyart, Marie-Cecile Lamy, Shaynoor Dramsi, Elisabeth Couve, Philippe Glaser, Patrick Trieu-Cuot
  • HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disorders
    Patent number: 8728748
    Abstract: The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and/or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and/or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: May 20, 2014
    Assignee: Institut Pasteur
    Inventors: Marie-Lise Gougeon, Beatrice Poirier-Beaudoin, Valerie Seffer, Hela Saidi
  • Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine
    Patent number: 8716013
    Abstract: Use of a recombinant lentiviral vector comprising a polynucleotide fragment encoding at least one protein of a virus of the family Flaviviridae or an immunogenic peptide of at least 8 amino acids of said protein, for preparing a pharmaceutical composition intended for the prevention and/or the treatment of a Flaviviridae infection in a sensitive species.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: May 6, 2014
    Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Philippe Despres, Pierre Charneau, Frédéric Tangy, Marie-Pascale Frenkiel
  • Genes associated with Leishmania parasite virulence
    Patent number: 8715697
    Abstract: The invention relates to the field of combating leishmaniases. Said invention results from the isolation, from wild isolates of Leishmania major, of a protein-coding gene known as LmPDI which has two regions that are identical to the sequence (Cys-Gly-His-Cys) of the potential active site of the protein disulphide isomerase (PDI). The LmPDI protein is predominantly expressed in the most virulent isolates of the parasite. Said protein forms a novel therapeutic target for developing anti-leishmaniasis medicaments and a novel element that can be used in the composition of immunogenic, and possibly vaccinating, preparations which are intended to protect a human or animal host against Leishmania.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: May 6, 2014
    Assignees: Institut Pasteur de Tunis, Institut Pasteur
    Inventors: Yosser Ben Achour, Mehdi Chenik, Hechmi Louzir, Koussay Dellagi
  • Neurovirulent strain of the West Nile virus and uses thereof
    Patent number: 8715693
    Abstract: Neuroinvasive and neurovirulent strain of the West Nile virus, named IS-98-ST1, nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules, and uses thereof.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: May 6, 2014
    Assignees: Institut Pasteur, Kimron Veterinary Institute
    Inventors: Philippe Despres, Vincent Deubel, Jean-Louis Guenet, Marie-Thérèse Drouet, Mertyn Malkinson, Caroline Banet, Marie-Pascale Frenkiel, Marie-Pierre Courageot, Fasséli Coulibaly, Adeline Catteau, Marie Flamand, Patrick Weber, Pierre-Emmanuel Ceccaldi
  • Sub-region of a plasmodium protein with improved vaccine potential, and medical uses thereof
    Patent number: 8716443
    Abstract: The present application relates to a sub-region of a Plasmodium protein, with improved vaccine potential, and to medical uses thereof, notably for treatment or diagnosis of malaria. The present invention notably provides unstructured or unfolded polypeptides deriving from the PFF0165c protein of P. falciparum 3D7. The polypeptides of the invention have a high antigenicity, a high immunogenicity, have a high parasite-killing activity in the ADCI assay, and are strongly associated with clinical protection against malaria, and. The present invention thereby provides a vaccine for the palliative and/or curative treatment of malaria, which is specifically intended for infants, toddlers, children under the age of 5, pregnant women.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: May 6, 2014
    Assignees: Institut Pasteur, Univiersite de Lausanne
    Inventors: Pierre Druilhe, Giampietro Corradin, Ali Jafarshad, Christian Roussilhon
  • MONITORING AND INHIBITING HUMAN IMMUNODEFICIENCY VIRUS INFECTION BY MODULATING HMGB1 DEPENDENT TRIGGERING OF HIV-1 REPLICATION AND PERSISTENCE
    Publication number: 20140120525
    Abstract: Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.
    Type: Application
    Filed: November 6, 2013
    Publication date: May 1, 2014
    Applicant: INSTITUT PASTEUR
    Inventors: Marie-Lise GOUGEON, Hela SAIDI, Marie-Therese MELKI, Beatrice POIRIER-BEAUDOIN, Valerie SEFFER
  • Assay for the diagnosis of flaviviral infection using antibodies with high affinity for NS1 protein of flavivirusi in hexameric form
    Patent number: 8709427
    Abstract: The invention concerns a method for early detection of a flavivirus-induced infection, comprising the detection of the flavivirus non-structural glycoprotein NS1 in a biological sample during the clinical phase of the infection, by an immunological method using at least two identical or different antibodies, the first antibody consisting of polyclonal or monoclonal antibodies pre-selected for their high affinity for said NS1 protein hexameric in shape.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: April 29, 2014
    Assignee: Institut Pasteur
    Inventors: Marie Flamand, Françoise Megret, Sophie Alcon, Antoine Talarmin, Philippe Despres, Vincent Deubel
  • Lentiviral gene transfer vectors and their medicinal applications
    Patent number: 8709799
    Abstract: The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors can be either integrative or non-integrative vectors. The invention encompasses prophylactic, therapeutic, symptomatic, and curative treatments of animals, including humans, as well as gene therapy and vaccination in vivo.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: April 29, 2014
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique, Theravectys
    Inventors: Pierre Charneau, Anne-Sophie Beignon, Frederic Philippe Coutant, Karine Courbeyrette
  • MUTATION WITHIN THE CONNEXIN 26 GENE RESPONSIBLE FOR PRELINGUAL NON-SYNDROMIC DEAFNESS AND METHOD OF DETECTION
    Publication number: 20140113285
    Abstract: A purified polynucleotide having a chain of nucleotides corresponding to a mutated sequence, which in a wild form encodes a polypeptide implicated in hereditary sensory defect, wherein said mutated purified polynucleotide presents a mutation responsible for prelingual non-syndromic deafness selected from the group consisting of a specific deletion of at least one nucleotide.
    Type: Application
    Filed: May 22, 2013
    Publication date: April 24, 2014
    Applicants: Centre National de la Recherche Scientifique, Institut Pasteur
    Inventors: Christine PETIT, Francoise Denoyelle-Gryson, Dominique Weil, Sandrine Marlin-Duvernois, Jean-Luc Guesdon
  • MONITORING AND INHIBITING HUMAN IMMUNODEFICIENCY VIRUS INFECTION BY MODULATING HMGB1 DEPENDENT TRIGGERING OF HIV-1 REPLICATION AND PERSISTENCE
    Publication number: 20140106334
    Abstract: Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.
    Type: Application
    Filed: March 14, 2013
    Publication date: April 17, 2014
    Applicant: INSTITUT PASTEUR
    Inventor: INSTITUT PASTEUR
  • Method and apparatus for imaging of features on a substrate
    Patent number: 8692876
    Abstract: A method for imaging features on a substrate, comprising scanning the substrate and producing an image thereof, overlaying a grid model on the image, fitting the grid model to the locations of at least some of the features on the image, and extracting images of the features.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: April 8, 2014
    Assignee: Institut Pasteur Korea
    Inventors: Auguste Genovesio, Neil Emans
  • Use of the ? chain of brain spectrin and fragments thereof, for diagnosing cerebral diseases
    Patent number: 8685662
    Abstract: The present invention pertains to a method for in vitro prognosticating and/or diagnosing cerebral cerebral malaria, wherein said method comprises a step of detecting non-erythroid spectrin or fragments thereof, and/or antibodies directed against non-erythroid spectrin, in a biological sample. Reagents and kits for performing this method are also disclosed.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: April 1, 2014
    Assignees: Institut Pasteur, Universite Pierre et Marie Curie (Paris 6)
    Inventors: Sylviane Pied, Vincent Guiyedi, Pierre-André Cazenave, Maryvonne Kombila, Youri Chanseaud
  • Use of Epigallocatechin Gallate as an Antiviral Agent against infections by the Hepatitis C Virus
    Publication number: 20140088184
    Abstract: The present invention relates to a flavonoid compound having the formula I, where R3, R5 and/or R7 is a group having the formula II, or R1 and R2 are both OH groups, or to one of the pharmaceutically acceptable salts or esters thereof, for use as an antiviral agent in the treatment and/or prevention of a hepatitis C virus (HCV) infection. The invention also relates to an ex vivo method for reducing the infectivity of HCV or for inactivating HCV, including a step of contacting said hepatitis C virus with a compound having the formula (I).
    Type: Application
    Filed: March 28, 2012
    Publication date: March 27, 2014
    Applicants: INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
    Inventors: Karin Seron, Jean Dubuisson, Yves Rouille, Czeslaw Wychowski
  • METHOD, PROBE AND KIT FOR DNA IN SITU HYBRIDATION AND USE THEREOF
    Publication number: 20140087378
    Abstract: The invention relates to a method for the detection of the occurrence of initiation of replication events in genomic DNA in a eukaryotic cell, involving contacting said eukaryotic cell comprising said genomic DNA with a first nucleotide probe, under conditions enabling in situ hybridization of said first nucleotide probe with a target region in the DNA genome, wherein said target region comprises a nucleic acid sequence which has no identified corresponding annealing RNA in a metabolically active cell and therefore remains RNA-free during transcription and replication of said DNA genome and detecting said first nucleotide probe hybridized to said DNA. Further detection of at least one RNA molecule can be achieved.
    Type: Application
    Filed: March 16, 2012
    Publication date: March 27, 2014
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEUR
    Inventors: Laurent Arnaud Chatre, Miria Ricchetti